Implementation of SARS-CoV-2 Monoclonal Antibody Infusion Sites at Three Medical Centers in the United States: Strengths and Challenges Assessment to Inform COVID-19 Pandemic and Future Public Health Emergency Use. (14th January 2023)

• Record Type: Journal Article
• Authors: Lambrou, Anastasia S.; Redd, John T.; Stewart, Miles A.; Rainwater-Lovett, Kaitlin; Thornhill, Jonathan K.; Hayes, Lynn; Smith, Gina; Thorp, George M.; Tomaszewski, Christian; Edward, Adolphe; Elías Calles, Natalia; Amox, Mark; Merta, Steven; Pfundt, Tiffany; Callahan, Victoria; Tewell, Adam; Scharf-Bell, Helga; Imbriale, Samuel; Freeman, Jeffrey D.; Anderson, Michael; Kadlec, Robert P.
• Is Part Of: Disaster medicine and public health preparedness. Volume 17(2023)
• Publication Date: 2023-01-14
• Subjects: COVID-19 pandemic -- infusion -- medical countermeasure -- monoclonal antibody -- pandemic response; Disaster medicine -- Periodicals; Emergency management -- Planning -- Periodicals; Public health -- Periodicals; 363.34
• DOI: 10.1017/dmp.2022.15
• Languages: English
• ISSNs: 1935-7893

Abstract

Abstract: Monoclonal antibody therapeutics to treat coronavirus disease (COVID-19) have been authorized by the US Food and Drug Administration under Emergency Use Authorization (EUA). Many barriers exist when deploying a novel therapeutic during an ongoing pandemic, and it is critical to assess the needs of incorporating monoclonal antibody infusions into pandemic response activities. We examined the monoclonal antibody infusion site process during the COVID-19 pandemic and conducted a descriptive analysis using data from 3 sites at medical centers in the United States supported by the National Disaster Medical System. Monoclonal antibody implementation success factors included engagement with local medical providers, therapy batch preparation, placing the infusion center in proximity to emergency services, and creating procedures resilient to EUA changes. Infusion process challenges included confirming patient severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positivity, strained staff, scheduling, and pharmacy coordination. Infusion sites are effective when integrated into pre-existing pandemic response ecosystems and can be implemented with limited staff and physical resources.